clinical trial

  1. NASH

    Nonalcoholic steatohepatitis (NASH) liver fibrosis is the new golden goose in the biotech space. More than 40 companies are taking part in clinical trials to bring the first NASH drug to market. Very few of them are close to seeing some success. NASH’s market value is set to increase to $21.5...

  2. Alzheimer’s disease trial - Axsome Therapeutics reports positive outcome

    Axsome Therapeutics stock skyrockets on positive outcome from Alzheimer's disease trial https://news.alphastreet.com/axsome-therapeutics-nasdaq-axsm-stock-almost-doubles-on-positive-outcome-from-alzheimers-disease-trial-in-premarket/
    • anonymous
    • Thread
    • alzhemier's disease axsome therapeutics biopharma clinical trial dementia drug eli lilly fda merck pfizer
    • Replies: 0
    • Forum: Pharma/Biotech Companies - In the News

  3. United Therapeutics signs a deal with Arena

    United Therapeutics signs an agreement with Arena in a deal worth $1.2 billion. It will pay $800 million as upfront payment to Arena and $400 million as potential milestone payments. This is what exactly Arena investors have been looking for. This will be a win-win deal for both the companies...
    • anonymous
    • Thread
    • agreement arena pharmaceuticals clinical trial deal drug fda pulmonary arterial hypertension united therapeutics
    • Replies: 0
    • Forum: United Therapeutics

  4. AbbVie’s elagolix meet phase III trial target

    AbbVie’s soon-to-become next blockbuster drug ELAGOLIX meet phase III trial target. Source: https://news.alphastreet.com/abbvies-elagolix-meet-phase-iii-trial-target/
    • anonymous
    • Thread
    • clinical trial drug trial
    • Replies: 3
    • Forum: AbbVie

  5. Obesity drug developer took a big step toward FDA approval

    Obesity drug developer, Gila Therapeutics, recently took a big step toward FDA approval for its new weight control treatment, completing its Phase I clinical trial in August. Gila is developing a novel intra-oral delivery of PYY, a well-known satiety hormone, to help patients reduce caloric...

  6. J&J discontinuing 2 promised blockbuster drugs

    While I was expecting this fate for sirukumab after Glaxo abandoned its partnership on this drug, talacotuzumab's discontinuation was totally unexpected. Two drugs that were so needed! Article source
Top Bottom
Back